Related Experiment Videos
Tolfenamic acid decreases migraine recurrence when used with sumatriptan
A V Krymchantowski1, M Adriano, D Fernandes
1Centro de Avaliação e Tratamento da dor de Cabeça do Rio de Janeiro, Brazil.
Cephalalgia : an International Journal of Headache
|May 11, 1999
Summary
Sumatriptan is effective for acute migraines but often recurs. Combining sumatriptan with tolfenamic acid significantly reduced migraine recurrence compared to sumatriptan alone.
Area of Science:
- Neurology
- Pharmacology
Background:
- Sumatriptan is a common acute migraine treatment.
- Migraine recurrence after sumatriptan use is a significant clinical challenge.
Purpose of the Study:
- To evaluate the efficacy of combining sumatriptan with tolfenamic acid in reducing migraine recurrence.
- To compare recurrence rates between sumatriptan monotherapy and a combination therapy.
Main Methods:
- Retrospective study of 50 migraine patients with frequent sumatriptan recurrence.
- Patients treated with sumatriptan 100 mg alone or in combination with tolfenamic acid 200 mg.
- Recurrence rates were analyzed based on treatment type.
Main Results:
- Sumatriptan monotherapy showed a recurrence rate of 62.5% (5 out of 8 attacks).
- The combination of sumatriptan plus tolfenamic acid reduced recurrence to 23.8% (57 out of 240 attacks).
- This represents a significant reduction in migraine recurrence.
Conclusions:
- The combination of sumatriptan and tolfenamic acid is effective in decreasing migraine recurrence.
- Further prospective, double-blind studies are warranted to confirm these findings.